26.15
0.77 (3.03%)
| Previous Close | 25.38 |
| Open | 25.55 |
| Volume | 20,620,217 |
| Avg. Volume (3M) | 34,064,528 |
| Market Cap | 6,052,618,752 |
| Price / Earnings (Forward) | 58.82 |
| Price / Sales | 3.00 |
| Price / Book | 14.53 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2026 |
| Profit Margin | 9.21% |
| Operating Margin (TTM) | 10.12% |
| Diluted EPS (TTM) | 0.680 |
| Quarterly Revenue Growth (YOY) | 110.70% |
| Quarterly Earnings Growth (YOY) | 344.70% |
| Total Debt/Equity (MRQ) | 11.54% |
| Current Ratio (MRQ) | 1.59 |
| Operating Cash Flow (TTM) | 334.34 M |
| Levered Free Cash Flow (TTM) | 213.45 M |
| Return on Assets (TTM) | 10.76% |
| Return on Equity (TTM) | 36.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Hims & Hers Health, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | 1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 11.13% |
| % Held by Institutions | 82.47% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Needham, 14.72%) | Buy |
| Median | 28.00 (7.08%) | |
| Low | 23.00 (B of A Securities, -12.05%) | Hold |
| Average | 26.80 (2.49%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 23.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 11 Mar 2026 | 29.00 (10.90%) | Buy | 25.88 |
| B of A Securities | 10 Mar 2026 | 23.00 (-12.05%) | Hold | 23.47 |
| Citigroup | 10 Mar 2026 | 24.00 (-8.22%) | Hold | 23.47 |
| Deutsche Bank | 10 Mar 2026 | 28.00 (7.07%) | Hold | 23.47 |
| Needham | 09 Mar 2026 | 30.00 (14.72%) | Buy | 22.16 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WELLS DAVID B | 23.85 | - | 48,400 | 1,154,340 |
| Aggregate Net Quantity | 48,400 | |||
| Aggregate Net Value ($) | 1,154,340 | |||
| Aggregate Avg. Buy ($) | 23.85 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WELLS DAVID B | Director | 26 May 2026 | Buy (+) | 48,400 | 23.85 | 1,154,340 |
| Date | Type | Details |
|---|---|---|
| 21 Apr 2026 | CNBC | Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access |
| 16 Apr 2026 | CNBC | RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves |
| 31 Mar 2026 | CNBC | Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |